Advertisement
LUNG vs SRTS
Which Stock Would AI Choose? Pulmonx Corporation (LUNG) vs. Sensus Healthcare (SRTS) Stock Comparison
Key Takeaways
- LUNG (Pulmonx Corporation) and SRTS (Sensus Healthcare) are both small-cap medical device companies, but they operate in different niches: minimally invasive lung treatment versus non-invasive skin cancer therapy.
- Pulmonx recently returned to year-over-year revenue growth and sharply narrowed its losses, reflecting improved commercial execution and cost discipline.
- Sensus Healthcare has posted steep revenue declines in recent quarters but carries a meaningful catalyst in new reimbursement (CPT) codes for superficial radiation therapy.
- Tickeron AI Verdict: Based on trend consistency, scale, and stability, the AI currently favors LUNG over SRTS, though both names carry elevated small-cap risk.
- For more detail, explore LUNG Major News, LUNG Today's Price Move, SRTS Major News, and SRTS Today's Price Move.
- To see how automated systems are trading these and other tickers, visit the Trending AI Robots page.
Introduction
Investors screening small-cap medical device names often encounter LUNG and SRTS together because both are development-stage, unprofitable healthcare companies competing for attention in the same broad sector. Despite superficial similarities, the two businesses differ sharply in their treatment technologies, revenue scale, and near-term momentum. This stock comparison is most relevant to growth-oriented traders and investors who are comfortable with elevated volatility and who want to weigh relative performance, catalysts, and market positioning before forming a view on either name.
LUNG Overview and Recent Performance
Pulmonx Corporation (LUNG) is a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its flagship Zephyr Endobronchial Valve is designed to improve breathing without major surgery, supported by the Chartis pulmonary assessment system and the LungTraX imaging platform.
In recent weeks, Pulmonx's quarterly results signaled a return to top-line growth in both its U.S. and international businesses, while its net loss narrowed by roughly 40% year over year. Management has reiterated full-year revenue guidance and highlighted cost-reduction initiatives that are improving operating leverage. A leadership transition, including the return of a prior chief executive, has been a focal point for sentiment, with analysts maintaining a broadly constructive view even as price targets have been recalibrated. Relative to the broader market, the stock has lagged in 2026 but has shown pronounced swings in response to earnings and analyst commentary.
SRTS Overview and Recent Performance
Sensus Healthcare (SRTS) manufactures and sells superficial radiation therapy (SRT) devices used to treat non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as other skin conditions like keloids. Its portfolio includes the SRT-100 systems and a growing software platform, Sensus Link.
Recent market activity for Sensus has been shaped by a difficult transition period. The company's quarterly revenue declined sharply year over year, driven in part by the absence of sales to its historically largest customer and by third-party financing delays that postponed revenue recognition on several high-value systems. At the same time, the company has a notable catalyst: new dedicated CPT (Current Procedural Terminology) reimbursement codes for SRT that took effect at the start of the year, which management credits with improving physician economics and strengthening its commercial pipeline. Analysts have kept a positive rating on the shares, though price targets have been reduced following recent results.
Trending AI Robots
For traders who prefer a systematic, data-driven approach, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron maintains hundreds of AI trading bots that collectively monitor and trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of covered securities. Because market conditions change, only the bots best suited to the current environment earn a place in this curated section. The page highlights key statistics and performance metrics to help users evaluate which strategies align with their objectives. Exploring the Trending AI Robots page is a practical way to see how algorithmic systems are positioning across names like these.
Head-to-Head Comparison
From a business-model standpoint, LUNG is further along the commercialization curve, generating significantly more revenue from a global installed base of pulmonology centers. SRTS, by contrast, is smaller in scale and has historically relied on a concentrated customer base, which introduces greater quarter-to-quarter variability in results.
On growth drivers, LUNG's momentum rests on rebuilding its U.S. sales force and expanding international adoption, while SRTS's outlook hinges on converting a strengthened pipeline into revenue under new reimbursement codes. Risk factors differ as well: LUNG faces execution risk tied to a leadership reset and cash burn, whereas SRTS faces customer concentration and the uncertain timing of large system orders. Market sentiment is mixed for both, but LUNG has shown more stable revenue trends and greater trading liquidity, while SRTS trades at a lower market capitalization with higher analyst-implied upside and correspondingly higher volatility.
Tickeron AI Verdict
Weighing trend consistency, revenue stability, scale, and the clarity of near-term catalysts, Tickeron's AI currently leans toward LUNG as the more favorable of the two. Pulmonx's return to year-over-year growth, narrowing losses, and reiterated guidance suggest a more orderly improvement in fundamentals, whereas Sensus Healthcare's sharp revenue contraction and financing-related disruptions introduce greater uncertainty despite its compelling reimbursement catalyst. This assessment reflects observable positioning rather than a definitive forecast, and it is best understood as a probabilistic, data-informed comparison between two speculative small-cap medical device stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LUNG is a Buy and SRTS is a Hold.
LUNG's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LUNG turned positive on October 20, 2026. Looking at past instances where LUNG's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on LUNG as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
LUNG moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LUNG crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +9.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUNG advanced for three days, in 214 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for LUNG moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 30 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 56 cases where LUNG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUNG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
LUNG broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LUNG entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.805) is normal, around the industry mean (4.142). P/E Ratio (-2.226) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.932) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LUNG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUNG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SRTS's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for SRTS moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 29 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SRTS broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRTS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SRTS as a result. In 74 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for SRTS just turned positive on November 03, 2026. Looking at past instances where SRTS's MACD turned positive, the stock continued to rise in 36 of 39 cases over the following month. The odds of a continued upward trend are 90%.
SRTS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +15.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTS advanced for three days, in 222 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.277) is normal, around the industry mean (4.142). P/E Ratio (-3.043) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.874) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SRTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LUNG | SRTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 46 | 96 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 28 Undervalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 34 | 56 | |
P/E GROWTH RATING 1..100 | 97 | 34 | |
SEASONALITY SCORE 1..100 | 3 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRTS's Valuation (27) in the Medical Specialties industry is in the same range as LUNG (28) in the null industry. This means that SRTS’s stock grew similarly to LUNG’s over the last 12 months.
SRTS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as LUNG (100) in the null industry. This means that SRTS’s stock grew similarly to LUNG’s over the last 12 months.
SRTS's SMR Rating (97) in the Medical Specialties industry is in the same range as LUNG (98) in the null industry. This means that SRTS’s stock grew similarly to LUNG’s over the last 12 months.
LUNG's Price Growth Rating (34) in the null industry is in the same range as SRTS (56) in the Medical Specialties industry. This means that LUNG’s stock grew similarly to SRTS’s over the last 12 months.
SRTS's P/E Growth Rating (34) in the Medical Specialties industry is somewhat better than the same rating for LUNG (97) in the null industry. This means that SRTS’s stock grew somewhat faster than LUNG’s over the last 12 months.
| LUNG | SRTS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 81% |
| Advances ODDS (%) | 8 days ago 81% | 2 days ago 81% |
| Declines ODDS (%) | 10 days ago 84% | 6 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LUNG’s FA Score shows that 1 FA rating(s) are green while SRTS’s FA Score has 1 green FA rating(s).
- LUNG’s FA Score: 1 green, 4 red.
- SRTS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LUNG’s TA Score shows that 5 TA indicator(s) are bullish while SRTS’s TA Score has 5 bullish TA indicator(s).
- LUNG’s TA Score: 5 bullish, 5 bearish.
- SRTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
LUNG (@Medical/Nursing Services) experienced а +2.94% price change this week, while SRTS (@Medical/Nursing Services) price change was +0.46% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
LUNG is expected to report earnings on Feb 24, 2027.
SRTS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
LUNG and
Correlation & Price change
A.I.dvisor indicates that over the last year, LUNG has been loosely correlated with SRTS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if LUNG jumps, then SRTS could also see price increases.
| Ticker / NAME | Correlation To LUNG | 1D Price Change % | ||
|---|---|---|---|---|
| LUNG | 100% | N/A | ||
| SRTS - LUNG | 57% Loosely correlated | +3.77% | ||
| BAX - LUNG | 53% Loosely correlated | +0.04% | ||
| ALGN - LUNG | 52% Loosely correlated | N/A | ||
| UTMD - LUNG | 32% Poorly correlated | -0.01% | ||
| KIDS - LUNG | 31% Poorly correlated | -1.50% | ||
More | ||||
SRTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, SRTS has been loosely correlated with LUNG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SRTS jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To SRTS | 1D Price Change % | ||
|---|---|---|---|---|
| SRTS | 100% | +3.77% | ||
| LUNG - SRTS | 57% Loosely correlated | N/A | ||
| HAE - SRTS | 45% Loosely correlated | +3.51% | ||
| AORT - SRTS | 34% Loosely correlated | -0.82% | ||
| GMED - SRTS | 32% Poorly correlated | -1.49% | ||
| MTD - SRTS | 28% Poorly correlated | -0.62% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QQLV | 27.04 | 0.09 | +0.33% |
| Invesco QQQ Low Volatility ETF (QQLV) | |||
| WEEI | 24.31 | 0.08 | +0.32% |
| Westwood Salient Enhanced Energy Income ETF (WEEI) | |||
| GAB | 5.36 | -0.02 | -0.37% |
| Gabelli Equity Trust (The) | |||
| PBP | 22.94 | -0.09 | -0.39% |
| Invesco S&P 500 BuyWrite ETF (PBP) | |||
| KMAR | 31.88 | -0.13 | -0.40% |
| Innovator U.S. Small Cap Power Buffer ETF - March (KMAR) | |||